Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.2.1.1 (
ACS
)
78,556
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Treating persistent neuropathic pain remains a major clinical challenge. Current conventional treatment approaches carry a substantial risk of toxicity and provide only transient pain relief. In this work, we show that the activity and expression of the inflammatory mediator secretory phospholipase-A
2
(sPLA
2
) enzyme increases in the spinal cord after painful
nerve root compression
. We then develop phospholipid micelle-based nanoparticles that release their payload in response to sPLA
2
activity. Using a rodent model of neuropathic pain, phospholipid micelles loaded with the sPLA
2
inhibitor, thioetheramide-PC (TEA-PC), are administered either locally or intravenously at the time of painful injury or 1-2 days afterward. Local micelle administration immediately after compression prevents pain for up to 7 days. Delayed intravenous administration of the micelles attenuates existing pain. These findings suggest that sPLA
2
inhibitor-loaded micelles can be a promising anti-inflammatory nanotherapeutic for neuropathic pain treatment.
ACS
Nano 2020 07 28
PMID:Phospholipase A
2
Inhibitor-Loaded Phospholipid Micelles Abolish Neuropathic Pain. 3248 51
